Literature DB >> 11439355

Heregulin-dependent translocation and hyperphosphorylation of ErbB-2.

W Zhou1, G Carpenter.   

Abstract

Previous data have shown that in several tumor cells lines the addition of heregulin results in the translocation of ErbB-4 to a detergent-insoluble membrane fraction where it is hypertyrosine phosphorylated. The data herein demonstrate that heregulin or betacellulin, but not EGF, promotes the rapid translocation of ErbB-2, the heterodimerization partner for ErbB-4, to the same detergent-insoluble fraction in T47 D mammary carcinoma cells. The translocation of ErbB-2 and ErbB-4, but not ErbB-3, to this detergent-insoluble fraction is readily detected 2 min after the addition of heregulin. ErbB-2 present in this detergent-insoluble membrane fraction is tyrosine phosphorylated to a level fourfold greater than the majority of cellular ErbB-2 present in the detergent-soluble membrane fraction. These results suggest the ligand-dependent formation of hyperphosphorylated ErbB-4/ErbB-2 dimers coordinate with translocation to a putative membrane microdomain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11439355     DOI: 10.1038/sj.onc.1204517

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  Association with membrane protrusions makes ErbB2 an internalization-resistant receptor.

Authors:  Anette M Hommelgaard; Mads Lerdrup; Bo van Deurs
Journal:  Mol Biol Cell       Date:  2004-01-23       Impact factor: 4.138

2.  Modulation of tumor growth by inhibitory Fc(gamma) receptor expressed by human melanoma cells.

Authors:  Lydie Cassard; Joël F G Cohen-Solal; Annie Galinha; Xavier Sastre-Garau; Claire Mathiot; Jérôme Galon; Thierry Dorval; Alain Bernheim; Wolf H Fridman; Catherine Sautès-Fridman
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

Review 3.  Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance.

Authors:  Alice Chung; Xiaojiang Cui; William Audeh; Armando Giuliano
Journal:  Clin Breast Cancer       Date:  2013-08       Impact factor: 3.225

4.  Ligand-dependent recruitment of the ErbB4 signaling complex into neuronal lipid rafts.

Authors:  Li Ma; Yang Z Huang; Graham M Pitcher; Juli G Valtschanoff; Ying H Ma; Lin Y Feng; Bai Lu; Wen C Xiong; Michael W Salter; Richard J Weinberg; Lin Mei
Journal:  J Neurosci       Date:  2003-04-15       Impact factor: 6.167

Review 5.  ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.

Authors:  David F Stern
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-03       Impact factor: 2.673

6.  Clathrin-independent endocytosis of ErbB2 in geldanamycin-treated human breast cancer cells.

Authors:  Daniel J Barr; Anne G Ostermeyer-Fay; Rachel A Matundan; Deborah A Brown
Journal:  J Cell Sci       Date:  2008-09-02       Impact factor: 5.285

7.  Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer.

Authors:  Alice Chung; Michael Choi; Bing-chen Han; Shikha Bose; Xiao Zhang; Lali Medina-Kauwe; Jessica Sims; Ramachandran Murali; Michael Taguiam; Marian Varda; Rachel Schiff; Armando Giuliano; Xiaojiang Cui
Journal:  Clin Breast Cancer       Date:  2015-06-19       Impact factor: 3.225

8.  The Dipole Potential Modifies the Clustering and Ligand Binding Affinity of ErbB Proteins and Their Signaling Efficiency.

Authors:  Tamás Kovács; Gyula Batta; Tímea Hajdu; Ágnes Szabó; Tímea Váradi; Florina Zákány; István Csomós; János Szöllősi; Peter Nagy
Journal:  Sci Rep       Date:  2016-10-24       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.